The effectiveness of concurrent training in lung cancer survivors: a systematic review Authors: Leonor Anjos, Mário Cardoso Marques, Dulce Esteves, Henrique Pereira Neiva, Ricardo Madeira, Adriana Maia, Diogo Luís Marques Published: 2026 ABSTRACT BackgroundLung cancer is associated with marked functional decline, symptom burden, and reduced quality of life across the cancer care continuum. Although exercise is increasingly supported in oncology, evidence specific to concurrent training in people with lung cancer remains limited and heterogeneous. This review synthesized the effects of concurrent training in adults with a confirmed lung cancer diagnosis who were undergoing or had completed oncological treatment, with pulmonary function as the prespecified primary outcome and physical fitness, functional capacity, and patient-reported outcomes as secondary outcomes. This review also describes exercise prescription characteristics according to the FITT-VP (frequency, intensity, time, type, weekly volume, and progression) framework.MethodsEligible studies were clinical trials that implemented concurrent training combining aerobic and resistance exercise within the same session. Searches were conducted in PubMed, Scopus, and Web of Science from inception to October 2025, completed by a supplementary CENTRAL research. Risk of bias was assessed using the Cochrane Risk of Bias tool for randomized trials and ROBINS-I V2 for non-randomized studies. Results were synthesized using a structured narrative approach, with relative differences calculated when pre-post data were available, but were interpreted only as descriptive indicators of within-group change and not as causal estimates of intervention effectiveness.ResultsTen studies met the inclusion criteria. Pulmonary outcomes showed limited and inconsistent responsiveness, with favorable changes in spirometric indices reported in only a minority of studies (6.3–10.5%), whereas most trials reported stability or small descriptive changes (−1.7% to 11.4%). More consistent favorable descriptive changes were observed in cardiorespiratory fitness (6.1–19%), functional capacity (6.4–9.1%), and muscular strength (5.5–42.8%). Favorable changes were also reported in selected patient-reported outcomes, including emotional well-being (9.2–12.6%), anxiety (12.5–24.6%), and sleep quality (28.6%). However, comparative effects were inconsistent across outcomes, and the evidence is limited by small sample sizes, methodological heterogeneity, inconsistent reporting, and risk of bias.ConclusionsConcurrent training may be associated with favorable changes in exercise capacity, functional performance, and muscular strength in people with lung cancer, whereas pulmonary function appears less responsive. Evidence remains limited by within-group findings, inconsistent between-group effects, heterogeneity, and risk of bias. Larger randomized trials with standardized FITT-VP reporting, adherence and safety monitoring, and longer follow-up are needed. Highlight box Key findings • Concurrent training may be associated with favorable descriptive changes in cardiorespiratory fitness, functional capacity, and muscular strength in people with lung cancer. In contrast, changes in spirometric pulmonary function were generally modest, inconsistent, and less clearly responsive across studies. What is known and what is new? • Exercise is increasingly supported in oncology, and concurrent training has been explored in several cancer populations. However, evidence specific to people with lung cancer has remained limited and heterogeneous. • This review suggests that concurrent training is more consistently associated with favorable descriptive changes in peak oxygen consumption (VO2peak), 6-minute walk distance, and muscular strength than with changes in spirometric indices. It also highlights that functional outcomes may be more responsive to exercise than pulmonary function outcomes, although mechanistic interpretations regarding respiratory preservation remain uncertain. What is the implication, and what should change now? • Concurrent training may represent a promising supportive exercise approach in lung cancer care, particularly when programs are individualized, supervised when feasible, and progressed according to symptoms, treatment phase, and functional status. However, current evidence does not support strong clinical recommendations. Future trials should adopt more rigorous designs, standardize FITT-VP (frequency, intensity, time, type, weekly volume, and progression) reporting, and systematically report adherence, retention, completion, intervention fidelity, adverse events, and treatment-phase-specific responses to strengthen future exercise prescription considerations. Introduction Background Lung cancer remains one of the most lethal malignancies worldwide and is the leading cause of cancer-related mortality in both men and women (1-3). Recent global estimates have reported more than 2 million new cases and 1.8 million deaths in 2020, highlighting its substantial epidemiological and clinical burden (2,3). Its development is influenced by both non-modifiable risk factors, such as age and hereditary genetic susceptibility, and modifiable determinants, including tobacco exposure, occupational carcinogens (e.g., asbestos, radon), air pollution, physical inactivity, poor diet, and alcohol consumption (4-11). From a clinical perspective, lung cancer is mainly classified into non-small cell lung cancer (NSCLC), which accounts for most cases, and small cell lung cancer (SCLC), a more aggressive subtype strongly associated with chronic tobacco exposure (12-14). Despite advances in screening and diagnostic strategies, many patients are still diagnosed at advanced stages (15,16). Treatment is individualized according to histology, stage, molecular profile, and functional status, and commonly includes surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapies (7,12,17-20). Although these approaches have improved survival, they are frequently associated with substantial adverse effects, including fatigue, dyspnea, muscle loss, reduced functional capacity, pain, anxiety, and depression, all of which may markedly impair quality of life and daily functioning (17,21-26). This clinical scenario reinforces the need for supportive, multidisciplinary strategies to attenuate treatment-related burden and preserve functional autonomy (22,24). Exercise has increasingly been recognized as a safe and effective adjunct therapy in oncology, with benefits reported across several cancer populations (27,28). In lung cancer specifically, emerging evidence suggests that exercise interventions may improve quality of life, symptom burden, functional capacity, and psychological well-being (29,30). Among available approaches, concurrent training, defined in this review as the combination of aerobic and resistance exercise within the same session, appears particularly relevant because it may address both cardiorespiratory and neuromuscular impairments commonly observed in this population (29-31). Rationale and knowledge gap Clinical trials conducted in people with lung cancer suggest that concurrent training may be feasible and may contribute to favorable changes in cardiorespiratory fitness, muscular strength, functional capacity, and selected patient-reported outcomes during or after oncological treatment (31-34). However, the available evidence remains limited and heterogeneous in terms of study design, outcome selection, clinical context, and exercise prescription characteristics (35,36). In particular, key FITT-VP (frequency, intensity, time, type, weekly volume, and progression) variables such as frequency, intensity, time, volume, and progression are not consistently reported, which limits the interpretation of dose-response patterns and reduces the applicability of findings to clinical practice (35,36). Pulmonary function was prioritized as the primary outcome because respiratory impairment is central to the clinical trajectory of many people with lung cancer, particularly across surgical, treatment, and rehabilitation contexts (17,21,30). Across the lung cancer care continuum, pulmonary status may be affected by treatment-related toxicity, radiation-related pulmonary injury, surgical procedures, and respiratory symptoms, which may contribute to functional vulnerability and rehabilitation needs (17,21,24,30). However, pulmonary function may be less responsive to exercise intervention than more patient-centered and exercise-responsive outcomes, such as cardiorespiratory fitness, functional capacity, dyspnea, health-related quality of life, frailty, and symptom burden (29,30,35,36). Moreover, no clear synthesis is currently available on how concurrent training influences pulmonary function in people with lung cancer. The extent to which concurrent training affects other important outcomes, including cardiorespiratory fitness, functional capacity, muscular strength, body composition, psychological indicators, and selected symptom-related outcomes, also remains insufficiently clarified. A focused synthesis of these effects, together with a structured description of exercise prescription parameters, is therefore needed to support a more cautious and evidence-informed interpretation of concurrent training across the lung cancer care continuum. Objective This review aimed to synthesize and critically analyze the available evidence on the effects of concurrent training in adults with lung cancer, with particular emphasis on pulmonary function as the prespecified primary outcome due to its clinical relevance for respiratory status across the lung cancer care continuum. Secondary aims were to examine the effects of concurrent training on cardiorespiratory fitness, functional capacity, muscular strength, body composition, and psychological outcomes. In addition, this review sought to describe exercise prescription characteristics according to the FITT-VP framework, with particular attention to intensity and volume, to understand better how concurrent training has been implemented in this population and to support evidence-informed interpretation and guide future clinical research. We present this article in accordance with the PRISMA reporting checklist (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0424/rc). Methods Review registration This systematic review has been registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD420251150032. Search strategy and eligibility criteria The literature search was conducted in the PubMed, Scopus, and Web of Science databases from inception to October 2025. Specific descriptors were used in combination with Boolean operators, either individually or jointly. The keywords applied were: (“Simultaneous training” OR “Simultaneous exercise” OR “Concurrent training” OR “Combined exercise” OR “Exercise” OR “Resistance Training”) AND (“Lung Neoplasms”). To increase search sensitivity for intervention studies, a supplementary search was conducted in CENTRAL via the Cochrane Library using expanded lung cancer- and exercise-related terms. The full search strategy, including the CENTRAL supplementary search, is provided in Table S1. Eligibility criteria were established according to the Population, Intervention, Comparison, Outcome, Study design (PICOS) framework, encompassing population, intervention, comparison, outcomes, and study design. Because the included studies involved adults undergoing active treatment, postoperative recovery, or post-treatment follow-up, the term “people with lung cancer” is used throughout the manuscript to describe the review population and avoid ambiguity associated with the term “survivor”. The inclusion and exclusion criteria are detailed in Table 1. Table 1Eligibility criteria according to the PICOS frameworkCategoryInclusion criteriaExclusion criteriaPopulationAdults (≥18 years) with a confirmed diagnosis of lung cancer who were undergoing or had completed any oncological treatment (e.g., surgery, chemotherapy, radiotherapy, immunotherapy, or targeted therapy)Children and adolescents (<18 years); individuals with other types of cancer without lung-specific dataInterventionConcurrent training programs (combination of aerobic and resistance exercise) performed within the same sessionOnline or home-based interventions; interventions in which aerobic and resistance training were not conducted within the same session; pulmonary rehabilitation-focused interventions without eligible same-session aerobic and resistance trainingComparisonIntra-group comparisons (pre- vs. post-intervention) and/or inter-group comparisons (intervention group vs. control/usual care group)Studies without pre-post data, between-group data, or insufficient reference values for outcome extractionOutcomesPre- and post-intervention changes in pulmonary function and/or physiological and functional outcomes, including FEV1, FVC, VO2max, VO2peak, 6-minute walk test, muscular strength (e.g., 1RM or xRM), functional capacity (e.g., sit-to-stand test), body composition (e.g., lean mass or body fat), and psychological or patient-reported outcomes (e.g., depression, anxiety, perceived well-being, or quality of life)Studies without relevant physiological, functional, pulmonary, or patient-reported outcomesStudy designRandomized and non-randomized clinical trials, quasi-experimental studies, or single-group pre-post intervention studies, published up to October 2025Systematic reviews, meta-analyses, editorials, case studies, protocols, observational or cross-sectional studies, and studies without access to full textFEV1, forced expiratory volume in one second; FVC, forced vital capacity; PICOS, Population, Intervention, Comparison, Outcome, Study design; RM, repetition maximum; VO2max, maximal oxygen consumption; VO2peak, peak oxygen uptake. Eligibility criteria according to the PICOS framework FEV1, forced expiratory volume in one second; FVC, forced vital capacity; PICOS, Population, Intervention, Comparison, Outcome, Study design; RM, repetition maximum; VO2max, maximal oxygen consumption; VO2peak, peak oxygen uptake. Screening process We exported all results and imported them into Rayyan for automatic deduplication. Two reviewers (L.A. and R.M.) independently screened titles/abstracts and full texts against the predefined criteria. For included studies, the following data were independently extracted into Microsoft Excel: study identification (study ID/author and year), study design, participant/sample characteristics, intervention and comparator details, exercise prescription variables mapped to the FITT-VP framework, outcomes assessed, adherence, retention, completion, adverse events when reported, and main findings/results, including descriptive pre-post percentage differences, reported between-group findings when available, and outcome interpretation notes. Adverse events were extracted when explicitly reported in the included studies; however, because adverse event definitions, monitoring procedures, and reporting formats were inconsistent across studies, safety outcomes were synthesized narratively and interpreted cautiously. Any disagreements were resolved by discussion, with a third reviewer (D.L.M.) acting as an arbiter when needed. Study risk of bias assessment The methodological quality of the included studies was assessed separately according to study design. For randomized controlled trials, risk of bias was assessed using the Cochrane Risk of Bias tool for randomized trials, considering the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. Domain-level judgments were classified as low, unclear, or high risk of bias. For non-randomized and single-group pre-post studies, risk of bias was assessed using the ROBINS-I V2 tool. The following domains were considered: bias due to confounding, bias in selection of participants into the study, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes, and bias in selection of the reported result. Judgments were classified as low, serious, or critical risk of bias, according to the signaling questions and domain-level guidance. Given the absence of random allocation and, in some studies, the absence of a concurrent comparison group, particular attention was paid to confounding and missing data. For single-group pre-post studies, confounding was judged conservatively because observed changes could not be clearly separated from time effects, natural recovery, postoperative recovery, regression to the mean, treatment-related changes, or baseline severity differences. Two reviewers (L.A. and R.M.) independently performed all assessments, and disagreements were resolved by consensus with a third reviewer (D.L.M.). Synthesis methods and data analysis Findings were synthesized using a structured narrative approach and summarized in standardized tables. Study design, sample characteristics, outcomes assessed, exercise prescription mapped to the FITT-VP framework, and outcome results were summarized and organized by domain, separating primary outcomes (pulmonary function) from secondary outcomes {cardiorespiratory fitness [peak oxygen consumption (VO2peak)], functional capacity [six-minute walk (6MWD), chair-stand, stair-run, Short Physical Performance Battery (SPPB)], muscular strength [leg press one repetition maximum (1RM), chest press 1RM, handgrip], body composition [body mass index (BMI), total muscle mass, body weight], and selected patient-reported outcomes/symptoms [Functional Assessment of Cancer Therapy-Lung (FACT-L) total score, Short Form 36 (SF-36) Physical Component Summary/Mental Component Summary (PCS/MCS), Hospital Anxiety and Depression Scale (HADS) anxiety/depression, European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status, and Pittsburgh Sleep Quality Index (PSQI)]}. To support descriptive interpretation across studies with heterogeneous designs, outcome measures, and reporting formats, percentage differences were calculated when pre- and post-intervention summary values were available. Percentage differences were calculated only as descriptive indicators of within-group change and were not interpreted as causal estimates of intervention effectiveness. Percentage difference was calculated as %∆ = (post-test/pre-test – 1) ×100, using mean values when reported, or median values when only medians were provided. In controlled trials, %∆ was calculated separately for each arm to describe the direction and magnitude of change over time, while interpretation prioritized between-group comparisons whenever these were reported. When between-group comparisons were unavailable, within-group percentage changes were interpreted cautiously as uncontrolled descriptive changes rather than evidence of intervention efficacy. This approach was used to facilitate descriptive comparison across heterogeneous studies; however, within-group pre-post changes may be influenced by spontaneous recovery, natural postoperative improvement, regression to the mean, time effects, and baseline severity differences, particularly in perioperative lung cancer populations. Therefore, percentage-difference metrics were not used as the basis for causal conclusions regarding intervention effectiveness. Outcome findings were synthesized narratively by considering the direction and magnitude of descriptive change, the presence and direction of between-group comparisons when available, the clinical and methodological context of each study, and the corresponding risk-of-bias judgments. Statistical significance was extracted as reported in the original studies, but it was not used as the sole basis for interpreting outcome patterns. Non-significant findings were not automatically interpreted as evidence of no effect, given the small sample sizes and limited statistical power of several included studies. Instead, findings were interpreted cautiously according to the consistency of results across studies, the comparability of outcome measures, and the strength of the available comparative evidence. Directionality was interpreted according to the outcome-specific meaning and instrument scoring conventions. For symptom-related outcomes, such as anxiety, depression, or sleep questionnaires, lower scores were considered indicative of improvement. When sufficient summary data were unavailable to compute %∆, outcomes were described narratively. Meta-analysis was not performed because outcome-level pooling was considered clinically and methodologically inappropriate. Although some outcomes, such as VO2peak, 6MWD, forced expiratory volume in one second (FEV1), and selected muscular strength measures, were reported in more than one study, the available data were not sufficiently comparable to generate meaningful pooled estimates. The included studies differed substantially in study design, treatment phase, disease stage, comparator condition, intervention duration, supervision level, exercise dose, outcome timing, and reporting format. In addition, some studies used single-group or non-randomized designs, while others used controlled designs, limiting the comparability of effect estimates across studies. For several outcomes, the required summary statistics for robust between-group effect size calculation, such as standard deviations of change scores or complete post-intervention group data, were inconsistently reported. Furthermore, muscular strength outcomes were assessed using different tests and units, including 1RM, handgrip strength, and repetition-based measures, which limited direct pooling. Therefore, pooling within-group pre-post changes or combining heterogeneous effect estimates across clinically distinct contexts could have produced misleading estimates of intervention effectiveness. For these reasons, a structured narrative synthesis was considered the most appropriate approach. The evidence-informed FITT-VP exercise prescription considerations presented in Table 2 were developed by the review authors after completion of data extraction and narrative synthesis. This process was descriptive and evidence-informed, rather than a formal guideline-development procedure. First, exercise prescription parameters, including frequency, intensity, time, type of exercise, volume, progression, and monitoring, were extracted from the included interventions and organized according to treatment context: perioperative phase, active oncological treatment, post-treatment or maintenance, and advanced disease or frailty. Second, the most commonly reported FITT-VP ranges were summarized across studies and interpreted in relation to the direction and consistency of the reported outcomes. Third, these ranges were contextualized against the methodological limitations, risk of bias, and heterogeneity of the available evidence. Therefore, the statements presented in Table 2 should be interpreted as provisional, evidence-informed exercise prescription considerations, not as strong clinical recommendations or formal clinical guidelines. Table 2Evidence-informed FITT-VP exercise prescription considerations derived from concurrent training studies in people with lung cancer across treatment contextsFITT-VP componentPerioperative (pre-post-surgery)During active treatmentPost-treatment or maintenanceAdvanced disease or frail patientsFrequency2 sessions/week, preferably supervised2–3 sessions/week, supervised when feasible2–3 sessions/week1–2 sessions/week, flexible schedulingIntensityAT: 40–60% VO2peak/VO2max progressed as toleratedAT: 50–70% VO2peak/VO2max adjusted to symptoms and treatment cyclesAT: 60–85% VO2peak/VO2max when toleratedAT: 30–50% VO2peak/VO2max symptom-limitedRT: 30–50% 1RMRT: 40–70% 1RMRT: 60–80% 1RM when tolerated; when power-oriented sets are included, ~30–60% 1RMRT: 20–40% 1RM; prioritize function; if machine-based power training is feasible, ~30–60% 1RMTimeAT: ~20 min aerobic work (e.g., 10–20 min stationary bike + walking-based warm–up 5–15 min)AT: ~10–15 min cycling interval training (supervised) + home walking 20–40 min (progressive: 20 → 30 → 40 min)AT: ~20 min aerobic work in standard sessions (e.g., treadmill/elliptical/bike), or 20–60 min depending on the aerobic prescriptionAT: 3–5 min stationary cycling endurance (symptom-limited/low burden)RT: ~30 min resistance work in standard sessions (machine-based + free weight/bodyweight) when sessions allocate 20 min aerobic + 30 min resistanceRT: ~90 min machine-based strength workRT: 30–60 min resistance trainingRT: ~30–40 min resistance/power + functional/balance tasksType of exercisesAT: walking or cyclingAT: stationary cyclingAT: continuous or interval-based aerobic trainingAT: stationary cyclingRT: prioritizing leg press and chest press, followed by seated row and lat pull-down/lateral machine (machine-based or equivalents)RT: typically, machine-based, prioritizing leg press and chest press, plus lat pull-down/lateral machine and seated row (or close equivalents)RT: progressed strength exercises anchored by leg press and chest press, plus seated row and lat pull-down (with additional accessory exercises as needed)RT: leg press and chest press, complemented by functional tasks (e.g., sit-to-stand) and band-based work as toleratedVolumeAT: 10–20 minAT: 15–30 minAT: 20–60 minAT: 5–15 minRT: 2–3 sets/exercise of 10 reps/exercise; emphasis on technique; maximal intended concentric velocity (as tolerated); controlled eccentric actionsRT: 3 sets/exercise of 5–8 reps/exercise; avoid training to failure; maximal intended concentric velocity only when symptom-stable; controlled eccentric actionsRT: 2–3 sets/exercise, typically 6–18 reps/exercise; maximal intended concentric velocity; controlled eccentric actionsRT: 3 sets/exercise of 8–12 reps/exercise; maximal intended concentric velocity; controlled eccentric actionsProgressionAT: increase walking speed when the patient completes 20 min continuously with symptoms and SpO2 within acceptable limits (≥88%); walking speed anchored to baseline 6MWT speed (e.g., corridor 80% and treadmill 70% initially)AT: progress walking duration 20 → 30 → 40 min across weeks as toleratedAT: midpoint reassessment (Week 8) of CPET to recalibrate training loads; non-linear/periodized progression of aerobic dose across blocks (weeks 1–2 vs. 3–8 vs. 9–16)AT: prioritize adherence: add very small steps (e.g., +1–3 min/session or +1 extra short bout/day); keep symptom-limitedRT: when patient completes all sets at the top rep range with good technique (RPE ~6–7/10), increase load ~2–5% (upper) or ~5–10% (lower)RT: reassess 1RM every ~2 weeks and adjust weights accordinglyRT: midpoint reassessment (week 8) of 1RM to recalibrate training loads; non-linear/periodized progression of load/rep ranges across blocks (weeks 1–2 vs. 3–8 vs. 9–16)RT: structured micro-progression in power RT: 30% 1RM (week 1) → 40% 1RM (weeks 2–3) → 50% 1RM (weeks 4–7) → 60% 1RM (weeks 8–10), with reps reducing 12 → 8MonitoringAT: symptoms, perceived exertion, clinical red flags, and heart rate monitorAT: symptoms, perceived exertion, clinical red flags, session tolerance, and heart rate monitorAT: symptoms, perceived exertion, clinical red flags, performance-based monitoring and reassessment, heart rate monitorAT: symptom-limited monitoring, clear stop criteria, heart rate monitorRT: movement velocity measurement may be considered when available and clinically appropriate to support load adjustment; optional strategy, not a core recommendationRT: movement velocity measurement may be considered when available and clinically appropriate to support load adjustment; optional strategy, not a core recommendationRT: movement velocity measurement may be considered when available and clinically appropriate to support load adjustment; optional strategy, not a core recommendationRT: movement velocity measurement may be considered when available and clinically appropriate to support load adjustment; optional strategy, not a core recommendationThis table provides evidence-informed exercise prescription considerations derived from the concurrent training protocols included in this review. These considerations were developed by the review authors after data extraction and narrative synthesis of the available studies and should not be interpreted as formal clinical guidelines or strong recommendations. Given the small number of studies, methodological heterogeneity, inconsistent reporting of FITT-VP variables, and risk of bias, the proposed ranges should be applied cautiously and individualized according to treatment phase, symptoms, comorbidities, functional capacity, safety considerations, and patient preferences. When cardiopulmonary testing is unavailable, aerobic intensity may be prescribed using perceived exertion, typically Borg 11–13 for moderate intensity and 14–16 for moderate-to-vigorous work, adjusted to symptoms and daily tolerance. Resistance intensity may be prescribed using repetition targets and submaximal effort, prioritizing safe technique and avoiding training to failure during active treatment or in frail patients. When power-focused resistance training is clinically appropriate, repetitions may be cued with maximal intended concentric velocity, as reported in selected protocols included in this review using approximately 30–60% 1RM. Across all phases, progression should be conservative, individualized, and guided by symptom response, treatment burden, and clinical supervision. 1RM, one repetition maximum; 6MWT, six-minute walk test; AT, aerobic training; CPET, cardiopulmonary exercise test; FITT-VP, frequency, intensity, time, type, weekly volume, and progression; rep, repetition; RPE, rating of perceived exertion; RT, resistance training; SpO2, peripheral capillary oxygen saturation; VO2max, maximum oxygen consumption; VO2peak, peak oxygen consumption. Evidence-informed FITT-VP exercise prescription considerations derived from concurrent training studies in people with lung cancer across treatment contexts This table provides evidence-informed exercise prescription considerations derived from the concurrent training protocols included in this review. These considerations were developed by the review authors after data extraction and narrative synthesis of the available studies and should not be interpreted as formal clinical guidelines or strong recommendations. Given the small number of studies, methodological heterogeneity, inconsistent reporting of FITT-VP variables, and risk of bias, the proposed ranges should be applied cautiously and individualized according to treatment phase, symptoms, comorbidities, functional capacity, safety considerations, and patient preferences. When cardiopulmonary testing is unavailable, aerobic intensity may be prescribed using perceived exertion, typically Borg 11–13 for moderate intensity and 14–16 for moderate-to-vigorous work, adjusted to symptoms and daily tolerance. Resistance intensity may be prescribed using repetition targets and submaximal effort, prioritizing safe technique and avoiding training to failure during active treatment or in frail patients. When power-focused resistance training is clinically appropriate, repetitions may be cued with maximal intended concentric velocity, as reported in selected protocols included in this review using approximately 30–60% 1RM. Across all phases, progression should be conservative, individualized, and guided by symptom response, treatment burden, and clinical supervision. 1RM, one repetition maximum; 6MWT, six-minute walk test; AT, aerobic training; CPET, cardiopulmonary exercise test; FITT-VP, frequency, intensity, time, type, weekly volume, and progression; rep, repetition; RPE, rating of perceived exertion; RT, resistance training; SpO2, peripheral capillary oxygen saturation; VO2max, maximum oxygen consumption; VO2peak, peak oxygen consumption. Results Study selection Figure 1 shows the study selection process. The search yielded a total of 2,236 records. After removing 670 duplicates, 1,566 unique articles were screened by title and abstract, and 1,547 were excluded. Nineteen full-text articles were assessed for eligibility, and 9 were excluded (home-based interventions, non-concurrent exercise modalities, non-concurrent delivery, or pulmonary rehabilitation-focused sessions). Consequently, 10 studies were included in this systematic review. The supplementary CENTRAL search retrieved 344 trial records; after title/abstract screening and assessment of potentially relevant records, no additional studies met the eligibility criteria. Flow diagram of the study screening process included in this review, prepared in accordance with PRISMA guidelines. Study characteristics and intervention Table 3 presents a concise overview of the included studies, summarizing sample characteristics, study design, outcomes assessed, and main findings. The studies are organized chronologically to facilitate comparison and critical appraisal of the evidence on exercise-based interventions in people with lung cancer. Table 3General characteristics of the included studiesStudyParticipantsStudy designOutcome measuresMain findings(31)Patients with inoperable lung cancer (NSCLC III–IV and SCLC-ED) undergoing chemotherapy; n=29; 13 men/16 women; age =63 years (range, 45–80 years)Pilot intervention study (non-randomized clinical trial)FEV1, VO2peak, 1RM (leg press, chest press, lat machine, abdominal crunch, lower back, and leg extension), 6MWT, BMI, FACT-LPulmonary function: FEV1 showed no significant within-group change as reported in the original study(37)Patients with lung cancer undergoing radical surgery (lobectomy/pneumonectomy); n=78 (IG =41, CG =37); 46 men/32 women; age =64–65 years (mean ± SD: IG, 64±10 years; CG, 65±9 years)Randomized clinical trial (supervised vs. unsupervised group)FEV1, FVC, 6MWT, SF-36Pulmonary function: no between-group differences were reported for FEV1 or FVC at 4 months or 1 year(38)Patients with resectable NSCLC undergoing lung resection (lobectomy/pneumonectomy); n=61 (IG =30, CG =31); IG: 13 men/17 women; CG: 15 men/16 women; age (years, mean ± SD): IG, 64.4±9.3; CG, 65.9±8.5 Randomized clinical trial (20-week intervention)FEV1, VO2peak, 1RM (leg press), handgrip, BMI, functional capacity (chair stand, stair run), SF-36Pulmonary function: TLco (%pred) showed a favorable within-group change; no between-group differences were reported for FEV1 (%pred) or MVV (%pred)(39)Patients with stage IIIb–IV NSCLC or SCLC-ED undergoing chemotherapy; n=114; 57 men/57 women; age =66 years (range, 31–88 years)Intervention study (pre-post) (non-randomized clinical trial)FEV1, VO2peak, 6MWT, 1RM (leg press, chest press, lat machine, abdominal crunch, lower back, leg extension), BMI, FACT-L, HADS (anxiety and depression)Pulmonary function: FEV1 showed no significant within-group change as reported in the original study(40)People with NSCLC (stage I–IIIA) 6-10 weeks post-lobectomy (or 4–8 weeks post-adjuvant chemotherapy); n=17 (EG =9, CG =8); 5 men/12 women; age (years, mean ± SD): total, 67±9; EG, 66±10; CG, 68±9Randomized clinical trial (8 weeks)VO2peak, 6MWT, muscle strength (quadriceps and handgrip), HRQoL (SF-36, FACT-L), anxiety/depression (HADS), pulmonary functionPulmonary function: no between-group differences were reported across spirometric or lung volume indices(41)Patients with stage I–IIIA NSCLC, 6–12 weeks post-surgery; n=17; 5 men/12 women; age =59 years [median (IQR): 44–63 years]Feasibility study (phase I) (non-randomized clinical trial)FEV1, 6MWT, SPPB, PSQI, SAS, SDS, EORTC-QLQ-C30, and LC13Pulmonary function: FEV1 showed a significant within-group increase in the original study(32)Patients with advanced inoperable lung cancer (stage IIIb–IV NSCLC or ES-SCLC) undergoing chemotherapy; n=218 (IG =110, CG =108); 107 men/111 women; age (years, mean ± SD): total, 64.4±8.5; IG, 65.2±8.2; CG, 63.5±8.7 Randomized clinical trialFEV1, VO2peak, 6MWT, 1RM, FACT-L, anxiety, and depression (HADS)Pulmonary function: no significant between-group difference was reported for FEV1(42)People with lung cancer post-lobectomy; n=9; gender: NR; age =61.9±13.6 yearsIntervention study (pre-post) (non-randomized clinical trial)FEV1, VO2peak, 1RM (lat pull down, shoulder press, chest press, seated row, leg curl, leg extension, and leg press), handgrip, quality of life (HRQoL), fatigue scalePulmonary function: FEV1 (%pred) showed a favorable within-group change; FVC findings were not consistent across reported values(43)Older adults with NSCLC (stages I–IV) receiving adjuvant/palliative treatment; n=26 (IG =19, CG =7); IG =15 men/4 women; CG =5 men/2 women; age (years, mean ± SD): IG, 74.5±3.6; CG, 79.0±3.0Quasi-experimental study (secondary analysis)Functional capacity, frailty status, and emergency visitsPulmonary function: NR; pulmonary outcomes were not assessed/reported(34)People with lung cancer and low cardiorespiratory fitness after definitive treatment (surgery + chemotherapy and/or radiotherapy); n=90 (AT =24, RT= 23, CT =20, AC =23); 31 men/59 women; age (years, mean ± SD): 65±9 (AT 64±9; RT 64±9; CT 63±11; AC 67±8)Randomized clinical trial with four arms (AT, RT, CT, control)VO2peak, 1RM (seated row, leg press), BMI, FACT-L, HR, ventilation, PROsPulmonary function: NR; pulmonary outcomes were not reported for the included concurrent training comparisonMain findings summarize the pulmonary outcome pattern reported in each original study and should not be interpreted as effect classifications based solely on statistical significance. 1RM, one repetition maximum; 6MWT, six-minute walk test; AC, attention control; AT, aerobic training; BMI, body mass index; CG, control group; CT, concurrent training; EG, experimental group; EORTC-QLQ-C30 and LC13, European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Lung Cancer Module; ES-SCLC, extensive-stage small cell lung cancer; FACT-L, Functional Assessment of Cancer Therapy-Lung; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; HR, heart rate; HRQoL, health-related quality of life; IG, intervention group; IQR, interquartile range; MVV, maximum voluntary ventilation; NR, not reported; NSCLC, non-small cell lung cancer; PROs, patient-reported outcomes; PSQI, Pittsburgh Sleep Quality Index; RT, resistance training; SAS, Self-Rating Anxiety Scale; SCLC-ED, extensive disease small cell lung cancer; SD, standard deviation; SDS, Self-Rating Depression Scale; SF-36, Short Form 36; SPPB, Short Physical Performance Battery; TLco, transfer factor of the lung cancer for carbon monoxide; VO2peak, peak oxygen consumption. General characteristics of the included studies Main findings summarize the pulmonary outcome pattern reported in each original study and should not be interpreted as effect classifications based solely on statistical significance. 1RM, one repetition maximum; 6MWT, six-minute walk test; AC, attention control; AT, aerobic training; BMI, body mass index; CG, control group; CT, concurrent training; EG, experimental group; EORTC-QLQ-C30 and LC13, European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Lung Cancer Module; ES-SCLC, extensive-stage small cell lung cancer; FACT-L, Functional Assessment of Cancer Therapy-Lung; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; HR, heart rate; HRQoL, health-related quality of life; IG, intervention group; IQR, interquartile range; MVV, maximum voluntary ventilation; NR, not reported; NSCLC, non-small cell lung cancer; PROs, patient-reported outcomes; PSQI, Pittsburgh Sleep Quality Index; RT, resistance training; SAS, Self-Rating Anxiety Scale; SCLC-ED, extensive disease small cell lung cancer; SD, standard deviation; SDS, Self-Rating Depression Scale; SF-36, Short Form 36; SPPB, Short Physical Performance Battery; TLco, transfer factor of the lung cancer for carbon monoxide; VO2peak, peak oxygen consumption. Overall, the ten included studies involved adults (n=659; 51.3% women and 47.3% men; gender not reported for 1.3% (n=9)] with lung cancer who were assessed across different points of the cancer care continuum, including active oncologic treatment (31,32,39), the early postoperative or immediate post-treatment phase (37,38,40-42), and longer-term rehabilitation and post-treatment settings (34,43). All studies implemented multicomponent concurrent exercise programs, predominantly delivered in supervised settings. When a comparator was used, it consisted of unsupervised delivery (37) or control/usual care/ attention control conditions (32,34,38,40,43). The most frequently assessed outcomes were cardiorespiratory and functional capacity [VO2peak (n=7), six-minute walk test (6MWT) (n=6), SPPB (n=1), chair-stand and stair-climb tests (n=1)], pulmonary function [FEV1 (n=7), forced vital capacity (FVC) (n=1), transfer factor of the lung cancer for carbon monoxide (TLco) (n=1), maximum voluntary ventilation (MVV) (n=1)], muscular strength [1RM (n=6), quadriceps strength (n=1), handgrip (n=3)], and health-related quality of life [FACT-L (n=5), SF-36 (n=3), EORTC QLQ-C30/Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) (n=1)]. Six studies examined symptoms and psychosocial/clinical indicators, including anxiety/depression (n=4), sleep quality (n=1), fatigue and frailty (n=1), and emergency department visits (n=1). Anthropometric measures, such as BMI, were reported in four studies. Favorable changes in exercise capacity were reported in six studies (31,34,38-40,42), although these findings included both within-group changes and between-group effects depending on study design. Favorable changes in muscular strength were also reported in six studies (31,32,34,38,39,42), with comparative evidence available only in selected controlled trials. Additional favorable findings were reported for health-related quality of life (HRQoL)/emotional well-being (31,32,37,38,41,42), sleep quality (41), anxiety/depression (32,39,41), and frailty/acute care utilization (43), but these outcomes were not consistently supported by between-group superiority across studies. Table 4 summarizes the main methodological characteristics of exercise interventions according to the FITT-VP model. In studies conducted during active oncologic treatment (31,32,39), programs lasted 6–12 weeks and included two supervised 90-minute sessions per week. Aerobic training was prescribed at ~60–95% VO2max/VO2peak, mainly on cycle ergometers, and resistance training at ~70–90% 1RM in resistance machines. Progression was achieved through increases in %1RM, repetitions, and/or interval intensity, often supported by regular 1RM reassessment. Table 4Description of the included studies according to the FITT-VP frameworkStudyDurationFrequencyIntensitySession timeType of exerciseTotal volumeProgression(31)6 weeks (during chemotherapy)2×/week (hospital)85–95% VO2max and 70–90% 1RM90 minAT: stationary cyclingAT: 10–15minAT & RT: every two weeksRT: LP, CP, LE, AC, LB, LMRT: 3 sets × 5–8 reps(37)10 weeks (3 weeks post-surgery)1×/weekAT: RPE 11–12 (weeks 1–4); RPE 13–16 (weeks 5–10)60 minAT: stationary cyclingAT: 10–20 minAT: gradual increase in number of intervals and intensity (RPE 12→16)RT: NRRT: arms (green Thera-band); trunk (abdominal, back); legs (step-ups, heel raises, sit-to-stands)RT: 1–2 sets × 6–10 reps (10–15 min)RT: progression in sets and reps(38)20 weeks (5–7 weeks post-surgery)3×/weekAT: 80–95% VO2max60 minAT: uphill treadmill walkingAT: not specifiedAT & RT: individualized and continuous, based on physical and emotional statusRT: 6–12RMRT: LP, LE, BE, SR, BC, CP, SPRT: 3 sets(39)6 weeks (during chemotherapy)2×/weekAT: 85–95% VO2max90 minAT: stationary cyclingAT: 10 minAT: NRRT: 70–90% 1RMRT: LP, CP, LM, AC, LB, LERT: 3 sets × 5–8 repsRT: biweekly 1RM reassessment with load adjustment(40)8 weeks (6–10 weeks post-surgery or 4–8 weeks post-chemotherapy)2×/weekAT: 70% 6MWT and 60–80% VO2max60 minAT: treadmill or cycling (interval)AT: 20 minAT: NRRT: NRRT: step-ups, elbow flexion, short-lever shoulder abduction, upper limbRT: 2–3 sets × 10 repsRT: NR(41)12 weeks (6–12 weeks post-surgery)2×/weekAT: 80% 6MWT90 minAT: treadmillAT: 15 minAT: progressive increase in duration and speed to maintain moderate intensity (Borg 4/10); RT: gradual increase in reps followed by load increments, adjusted individually.RT: 4/10 RPERT: seated knee extension, seated shoulder flexion, shoulder shrug, seated bilateral shoulder row, seated heel raise, seated marching on the spot.RT: 3 sets × 8–15 reps(32)12 weeks (during chemotherapy)2×/weekAT: 60–80% VO2max90 minAT: stationary cyclingAT: 10 minAT: interval aerobic training (70–90% HRmax) with individualized progressionRT: 70–90% 1RMRT: LP, CP, LPD, LERT: 3 sets × 5–8 repsRT: Biweekly load adjustment (1RM)(42)12 weeks (post-surgery)3×/weekAT: 30–60% HRR60 minAT: treadmill, elliptical, cyclingAT: 20 minAT: NRRT: NRRT: LP, CP, SR, deadlifts, squats, bent-over row, bench press, bodyweight exercisesRT: 30 minRT: NR(43)10 weeks2×/weekAT: 50–80% VO2max45–50 minAT: cycling. RT: LP, CP, shoulder flexion/extension, shoulder abduction/adduction, chest press, HAB.AT: 3–5minAT: NRRT: 30–60% 1RMRT: 2–3 × 10–15 rep.RT: increment in %RM(34)16 weeks3×/weekAT: 55–95% VO2max30–90 minAT: stationary cycle ergometer. RT: CP, SR, LPD, BC, LP, LC, LE, pec deck, triceps extension, push-up, HAB, HAD, step-up, sit-to-standAT: 4–10 intervals of 60–120s VO2peak, followed by 120–180 s active recoveryAT: gradual increase in aerobic training intensity (based on ventilatory thresholds) and durationRT: 50–85% 1RMRT: 2–3 sets × 6–18 repsRT: 1RM adjusted biweekly with weekly variation in load and volume1RM, one repetition maximum; 6MWT, six-minute walk test; AC, abdominal crunch; AT, aerobic training; BC, bicep curl; BE, back extension; CP, chest press; CPET, cardiopulmonary exercise test; FITT-VP, frequency, intensity, time, type, weekly volume, and progression; HAB, hip abduction; HAD, hip adduction; HRR, heart rate reserve; LB, lower back; LC, leg curl; LE, leg extension; LM, lateral machine; LP, leg press; LPD, lateral pull down; NR, not reported; reps, repetitions; RM, repetition maximum; RPE, rating of perceived exertion; RT, resistance training; SP, shoulder press; SpO2, peripheral capillary oxygen saturation; SR, seated row; VO2max, maximum oxygen consumption; VO2peak, peak oxygen consumption. Description of the included studies according to the FITT-VP framework 1RM, one repetition maximum; 6MWT, six-minute walk test; AC, abdominal crunch; AT, aerobic training; BC, bicep curl; BE, back extension; CP, chest press; CPET, cardiopulmonary exercise test; FITT-VP, frequency, intensity, time, type, weekly volume, and progression; HAB, hip abduction; HAD, hip adduction; HRR, heart rate reserve; LB, lower back; LC, leg curl; LE, leg extension; LM, lateral machine; LP, leg press; LPD, lateral pull down; NR, not reported; reps, repetitions; RM, repetition maximum; RPE, rating of perceived exertion; RT, resistance training; SP, shoulder press; SpO2, peripheral capillary oxygen saturation; SR, seated row; VO2max, maximum oxygen consumption; VO2peak, peak oxygen consumption. In the early postoperative or immediate post-treatment phase (37,38,40-42) (3–12 weeks after surgery), programs ranged from 8 to 20 weeks, with one to three supervised sessions per week lasting 60–90 minutes. Aerobic exercise was performed on treadmills or cycle ergometers, with intensity guided by RPE, VO2-based targets, or 6MWT-derived thresholds, while resistance training involved therabands, bodyweight, or machine-based exercises. Progression relied on gradual increases in duration, speed, RPE, sets, and repetitions, with individualized adjustments according to clinical and functional status. In longer-term rehabilitation and survivorship settings (34,43), interventions lasted 10–16 weeks, with two to three supervised sessions per week of 30–90 minutes. Aerobic work on a cycle ergometer was prescribed at 50–95% VO2max and combined with multi-joint resistance exercises using machines, free weights, and bodyweight. Progression strategies included periodized load adjustments based on ventilatory thresholds and 1RM, as well as stepwise increases in training intensity and volume to maintain an appropriate overload stimulus. Risk of bias in studies Across the five randomized controlled trials, risk-of-bias judgments were summarized using the Cochrane Risk of Bias tool domains. Random sequence generation, blinding of outcome assessment, and other sources of bias were judged as low risk in all studies (5/5; 100%). Allocation concealment was consistently rated as high risk (5/5; 100%), reflecting insufficient reporting or inadequate concealment procedures. Blinding of participants and personnel was judged as high risk in three trials (3/5; 60%) and low risk in two trials (2/5; 40%), which is consistent with the practical difficulty of blinding participants and intervention personnel in exercise-based interventions. Incomplete outcome data were classified as unclear risk in all studies (5/5; 100%), mainly due to incomplete reporting of attrition handling or uncertainty regarding the impact of missing data. Selective reporting was considered low risk in four trials (4/5; 80%) and unclear risk in one trial (1/5; 20%). Overall, risk-of-bias concerns in randomized trials were mainly related to allocation concealment, blinding of participants and personnel, and incomplete outcome data. For non-randomized and single-group pre-post studies, Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-I) judgments were mainly driven by bias due to confounding and missing data. Bias due to confounding was judged as serious in all non-randomized studies (5/5; 100%), reflecting the absence of random allocation and, in several cases, the absence of a concurrent comparator. In single-group pre-post designs, observed changes could not be clearly separated from spontaneous recovery, postoperative recovery, regression to the mean, time effects, treatment-related changes, or baseline severity differences. Bias due to missing data was judged as critical in four studies (4/5; 80%) and low in one study (1/5; 20%), depending on attrition, completeness of outcome reporting, and whether missingness could plausibly be related to the intervention or outcomes. All other ROBINS-I domains, including selection of participants, classification of interventions, deviations from intended interventions, measurement of outcomes, and selection of the reported result, were judged as low risk in all studies (5/5; 100%). Overall, four non-randomized studies were judged as having critical risk of bias (4/5; 80%), while one study was judged as having lower overall risk (1/5; 20%). Risk-of-bias graphs and study-level summaries are presented in Figures S1-S3. Changes in outcome measures Table 5 presents the changes in pulmonary function. Across spirometric measures reported as percentage change, within-group values ranged from −1.7% to +16.8% overall, with FEV1 ranging from −1.7% to +11.4% (31,32,39,41), and FVC increasing by +13.7% to +16.8% in the study reporting post-intervention and follow-up values (37). In that controlled trial, the experimental group showed within-group increases in FEV1 of +8.1% at post-intervention and +5.8% at follow-up, and in FVC of +13.7% at post-intervention and +16.8% at follow-up, with smaller increases in the control group (37). Percent-predicted indices were reported less frequently and showed modest within-group increases, with FEV1 (%pred) increasing by 6.3% to 9.6% (38,42) and FVC (%pred) increasing by 6.6% (42). In addition, a controlled perioperative trial reported within-group increases in other pulmonary-related percent-predicted outcomes, including MVV (%pred) (+5.9%) and TLco (%pred) (+8.7%) (38). Table 5Pulmonary function outcomes across included studies, showing descriptive within-group percentage differences for the EG and, when available, reported between-group findingsPulmonary function outcomeDescriptive within-group change in EG, %Reported EG vs. CG finding, when availableFEV1 (L)+10.5% (41); +11.4% (31); 0.0% (39); −1.7% (32)Post-intervention: EG +8.1% vs. CG +5.3%; follow-up: EG +5.8% vs. CG +3.2% (37). No significant between-group difference was reportedFEV1 (%pred)+6.3% (42)EG +9.6% vs. CG +8.4% (38). No significant between-group difference was reportedFVC (L)NRPost-intervention: EG +13.7% vs. CG +8.0%; follow-up: EG +16.8% vs. CG +9.8% (37). No significant between-group difference was reportedFVC (%pred)+6.6% (42)NRMVV(%pred)NREG +5.9% vs. CG +1.1% (38). No significant between-group difference was reportedTLco (%pred)NREG +8.7% vs. CG +2.4% (38). Reported between-group finding should be stated according to the original studyPercentage differences are descriptive and should not be interpreted as causal estimates of intervention effectiveness. Percentage differences were calculated as (post/pre – 1) ×100 when sufficient data were available. Values are presented as descriptive within-group changes for the experimental group and, when available, as arm-specific percentage changes for experimental and control groups in controlled trials. These values should not be interpreted as causal estimates of intervention effectiveness. Reported between-group findings reflect the statistical comparisons described in the original studies. Non-significant findings should not be interpreted as evidence of no effect, particularly given the small sample sizes and limited statistical power of several studies. %pred, percent predicted; CG, control group; EG, experimental group; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MVV, maximum voluntary ventilation; NR, not reported; TLco, transfer factor of the lung cancer for carbon monoxide. Pulmonary function outcomes across included studies, showing descriptive within-group percentage differences for the EG and, when available, reported between-group findings Percentage differences are descriptive and should not be interpreted as causal estimates of intervention effectiveness. Percentage differences were calculated as (post/pre – 1) ×100 when sufficient data were available. Values are presented as descriptive within-group changes for the experimental group and, when available, as arm-specific percentage changes for experimental and control groups in controlled trials. These values should not be interpreted as causal estimates of intervention effectiveness. Reported between-group findings reflect the statistical comparisons described in the original studies. Non-significant findings should not be interpreted as evidence of no effect, particularly given the small sample sizes and limited statistical power of several studies. %pred, percent predicted; CG, control group; EG, experimental group; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MVV, maximum voluntary ventilation; NR, not reported; TLco, transfer factor of the lung cancer for carbon monoxide. Changes in secondary outcomes are reported in Table 6. Extended secondary outcomes are reported in Table S2. Across studies assessing VO2peak, within-group changes ranged from +1.4% to +27.5% (31,32,38-40,42). Functional walking capacity (6MWD) showed descriptive within-group changes ranging from +6.4% to +15.2% overall, with short-term post-intervention gains of 6.4% to 14.3% (31,32,37,39-41) and a follow-up improvement of 15.2% in the study reporting 1-year values (37). Additional functional tests were less frequently reported: in one controlled perioperative trial, chair-stand performance showed a descriptive within-group change of +25.4%, and stair-run performance showed a descriptive within-group change of +21.3% (38), whereas SPPB showed no significant change (0.0%) in another study (41). Strength outcomes showed the largest descriptive within-group percentage changes, with leg press 1RM ranging from +20.4% to +42.8% (31,32,38,39,42) and chest press 1RM from +9.1% to +41.8% (31,32,39,42). Body composition changes were small and inconsistently reported, with BMI increasing by 0.4% to 2.8% across studies reporting this outcome (31,38,39), while total muscle mass increased by 3.2% in one controlled trial (38). For patient-reported outcomes and symptoms, FACT-L total score changes ranged from +0.9% to +5.6% across studies reporting within-group values (31,32,39,40), anxiety symptoms (HADS-A) decreased by −12.5% to −24.6% (32,39,41), and PSQI decreased by −28.6% in one study, suggesting a favorable within-group change in sleep quality (41). Table 6Secondary outcomes across included studies, organized by domain, showing descriptive within-group percentage differences for the EG and, when available, reported between-group findingsOutcome measuresDescriptive within-group % change in EGReported EG vs. CG finding, when availablePeak cardiopulmonary function VO2peak (L/min)+6.1% (31); +7.7% (39); +13.5% (40); +1.4% (32)EG +27.5% vs. CG +8.6% (38); EG +13.5% vs. CG −4.6% (40); NR (34) VO2peak (mL/kg/min)+8.3% (40); +19.0% (42); +2.4% (32)EG +21.4% vs. CG +5.0% (38); EG +8.3% vs. CG −4.3% (40); NR (34)Functional capacity 6MWD (m)+7.5% (31); +6.4% (39); +8.3% (40); +10.8% (41); +8.6% (32)EG +8.3% vs. CG −1.7% (40); post-intervention: EG +14.3% vs. CG +13.5%; follow-up: EG +15.2% vs. CG +14.7% (37) Chair stand (No. Rep)NREG +25.4% vs. CG +7.0% (38) Stair run (No. Steps)NREG +21.3% vs. CG +8.8% (38) SPPB0.0% (41)NRMuscle strength Leg press 1RM (kg)+23.4% (31); +20.4% (39); +36.1% (32)EG +20.8% vs. CG −1.6% (38) Leg press 1RM (lbs)+42.8% (42)NR (34) Chest press 1RM (kg)+30.8% (31); +17.7% (39); +9.1% (32)NR Chest press 1RM (lbs)+41.8% (42)NR (34) Handgrip (kg)NREG +7.0% vs. CG +1.2% (38) Handgrip: right (lbs)+11.5% (42)NR Handgrip: left (lbs)+10.2% (42)NRBody composition BMI (kg/m2)+0.8% (31); +0.4% (39)EG +2.8% vs. CG +2.1% (38) Total muscle mass (kg)NREG +3.2% vs. CG +0.3% (38) Weight (kg)NRNR (34)Patient-reported outcomes/symptoms FACT-L total score+2.8% (31); +1.7% (39); +0.9% (40); +5.6% (32)EG +0.9% vs. CG +16.9% (40); NR (34) SF-36 PCS+4.4% (40)Post-intervention: EG +17.2% vs. CG +8.0%; follow-up: EG +13.1% vs. CG +19.8% (37); EG +4.4% vs. CG −4.8% (40) SF-36 MCS−7.3% (40)Post-intervention: EG +9.6% vs. CG +12.0%; follow-up: EG +11.7% vs. CG +21.4% (37); EG −7.3% vs. CG +10.9% (40) Anxiety (HADS-A)−12.5% (39); −16.3% (41); −24.6% (32)NR Depression (HADS-D)−11.3% (39); −13.9% (41); −25.0% (32)NR EORTC QLQ-C30 global health status+1.4% (40); +19.9% (41)EG +1.4% vs. CG −3.0% (40) PSQI−28.6% (41)NRPercentage differences are descriptive and should not be interpreted as causal estimates of intervention effectiveness. Percentage differences were calculated as (post/pre – 1) ×100 when sufficient data were available. Values are presented as descriptive within-group changes for the experimental group and, when available, as arm-specific percentage changes for experimental and control groups in controlled trials. These values should not be interpreted as causal estimates of intervention effectiveness. Reported between-group findings reflect the statistical comparisons described in the original studies. Non-significant findings should not be interpreted as evidence of no effect, particularly given the small sample sizes and limited statistical power of several studies. For symptom-related outcomes, lower scores indicate favorable change. 1RM, one repetition maximum; 6MWD, six-minute walk distance; 6MWT, six-minute walk test; BMI, body mass index; CG, control group; EG, experimental group; EORTC QLQ-C30, European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Lung Cancer Module; FACT-L, Functional Assessment of Cancer Therapy-Lung; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS Anxiety subscale; HADS-D, HADS Depression subscale; MCS, Mental Component Summary; NR, not reported; PCS, Physical Component Summary; PSQI, Pittsburgh Sleep Quality Index; Rep, repetition; SF-36, Short Form 36; SPPB, Short Physical Performance Battery; VO2peak, peak oxygen consumption. Secondary outcomes across included studies, organized by domain, showing descriptive within-group percentage differences for the EG and, when available, reported between-group findings Percentage differences are descriptive and should not be interpreted as causal estimates of intervention effectiveness. Percentage differences were calculated as (post/pre – 1) ×100 when sufficient data were available. Values are presented as descriptive within-group changes for the experimental group and, when available, as arm-specific percentage changes for experimental and control groups in controlled trials. These values should not be interpreted as causal estimates of intervention effectiveness. Reported between-group findings reflect the statistical comparisons described in the original studies. Non-significant findings should not be interpreted as evidence of no effect, particularly given the small sample sizes and limited statistical power of several studies. For symptom-related outcomes, lower scores indicate favorable change. 1RM, one repetition maximum; 6MWD, six-minute walk distance; 6MWT, six-minute walk test; BMI, body mass index; CG, control group; EG, experimental group; EORTC QLQ-C30, European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Lung Cancer Module; FACT-L, Functional Assessment of Cancer Therapy-Lung; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS Anxiety subscale; HADS-D, HADS Depression subscale; MCS, Mental Component Summary; NR, not reported; PCS, Physical Component Summary; PSQI, Pittsburgh Sleep Quality Index; Rep, repetition; SF-36, Short Form 36; SPPB, Short Physical Performance Battery; VO2peak, peak oxygen consumption. Between-group comparisons were heterogeneous across controlled designs and outcome domains. One trial reported a significant between-group improvement only for SF-36 Bodily Pain at post-intervention, with no sustained between-group differences at follow-up (37). A controlled perioperative trial reported significant between-group improvements across multiple domains, including performance-related outcomes (chair-stand +25.4% vs. +7.0%, stair run +21.3% vs. +8.8%), strength (leg press 1RM +20.8% vs. −1.6%, handgrip +7.0% vs. +1.2%), selected body composition indicators (BMI +2.8% vs. +2.1%, total muscle mass +3.2% vs. +0.3%), and quality of life outcomes (38). Another controlled trial reported significant between-group improvements for VO2peak (+13.5% vs. −4.6%) and 6MWD (+8.3% vs. −1.7%), while other assessed outcomes generally showed no significant between-group differences (40). For the multi-arm trial, only the concurrent training arm versus control was considered, and several outcomes were not reported or were insufficient for percentage-difference calculations (34). One additional trial could not be summarized using percentage differences because of the outcome reporting format. However, it reported no significant between-group differences in mortality or hospital readmissions, and fewer emergency department visits in the intervention group at one-year post-intervention (43). Discussion Main findings This review showed that pulmonary function, the primary outcome, had modest, less consistent responses to concurrent training in people with lung cancer. Across studies, spirometric measures were often stable. When statistically significant improvements were observed, these tended to be isolated findings rather than a uniform pattern across trials and indices, suggesting limited responsiveness of lung function outcomes to exercise compared with other domains (31,32,37-42). In contrast, secondary outcomes showed more frequent favorable descriptive changes, particularly for cardiorespiratory fitness, functional capacity, and muscular strength. However, these findings should be interpreted cautiously because several favorable changes were based on within-group pre-post comparisons, whereas between-group superiority over usual care or comparator conditions was less consistent across outcomes and study designs (31,32,34,37-43). Patient-reported outcomes also showed favorable changes in some studies, particularly in selected quality-of-life domains and symptom-related measures, but comparative evidence was limited and heterogeneous. Overall, the results align with broader exercise-oncology guidance supporting individualized and progressive programs combining aerobic and resistance exercise to improve physical function and reduce symptom burden during and after treatment (44,45). Nevertheless, lung cancer-specific evidence remains heterogeneous, and prior syntheses similarly indicate that favorable changes tend to be more consistent for exercise capacity and muscle strength than for spirometric indices, where effects are often limited or inconsistent (46,47). Variability in study design, FITT-VP prescription, comparator conditions, and intervention duration also constrain interpretation across trials. Effect of concurrent training on pulmonary function In general, the included studies demonstrated low, non-significant within-group changes in spirometric outcomes after concurrent training programs. A statistically significant increase in FEV1 was reported in one study (41), and percent-predicted spirometric values improved in one study (42), while other studies reported stability or non-significant changes in spirometric measures (31,32,37,39). This pattern is plausible because spirometric volumes and related indices are strongly shaped by the extent of lung resection and the high prevalence of concomitant obstructive lung disease in lung cancer populations (48) and may be further constrained by treatment-related pulmonary injury, which can limit the reversibility of pulmonary function compared with outcomes driven mainly by peripheral conditioning (49). From a FITT-VP perspective, even when aerobic training is prescribed at ~50–95% VO2peak/VO2max and/or Borg ~11–16 and progressed appropriately, adaptations may be reflected more consistently in functional tolerance and exercise capacity than in marked increases in spirometric volumes (34,50,51). However, this interpretation should be considered cautiously because ventilatory efficiency and other mechanistic respiratory outcomes were not consistently assessed across the included studies. Accordingly, concurrent training may be more consistently associated with functional tolerance and exercise capacity than with large spirometric improvements. Whether concurrent training preserves respiratory function cannot be firmly established from the available evidence, because pulmonary outcomes were inconsistently reported and mechanistic respiratory measures were rarely assessed. In perioperative and early rehabilitation contexts, monitoring respiratory status may therefore be more appropriate than expecting substantial spirometric gains (52-61). Effect of concurrent training on cardiorespiratory fitness and functional capacity Cardiorespiratory fitness and walking capacity showed the most consistent favorable descriptive changes across the included studies. Within-group increases in VO2peak were reported in several interventions (31,39,42), and one additional trial reported only a small, non-significant change (32). Within-group increases in 6-minute walk distance were reported in three studies (31,32,39), with further improvements reported, although not always statistically significant in others (37,40,41). Between-group findings from controlled trials were also most evident for exercise capacity outcomes: one study reported between-group differences favoring the exercise group for VO2peak and 6-minute walk distance (40), and another study reported greater improvements in VO2peak for the concurrent training arm compared with the control arm (34). In contrast, outcomes in other domains were more variable. These results are consistent with the FITT-VP profiles summarized in this review. A training frequency of 2–3 times per week, typically over 8 to 20 weeks, using moderate to vigorous aerobic intensity prescribed predominantly within ~50–95% of HRmax/HRR/VO2peak, with targets in some studies derived from the 6-minute walk test when cardiopulmonary testing was unavailable (38,40), alongside structured progression, is more likely to elicit adaptations that are reflected in improved functional exercise capacity (38,40,62). A reasonable hypothesis is that concurrent training may improve oxygen transport and utilization and increase peripheral efficiency, which may explain why VO2peak and functional walking outcomes respond more consistently than spirometric indices (47). Notably, favorable changes in exercise capacity were reported across different clinical contexts, suggesting that, when tailored and progressed appropriately, aerobic training can remain responsive even during active treatment, although tolerance and progression should be adjusted to the phase and symptom burden (33,38,44,47,52,63). Effect of concurrent training on muscular strength and body composition Strength outcomes demonstrated frequent favorable within-group changes across multiple measures. Statistically significant within-group increases were reported for leg press 1RM and chest press 1RM in three studies (31,32,39). Favorable within-group changes were also observed across additional resistance exercises in two studies (31,39), with further upper- and lower-body strength gains reported in one study using multiple resistance exercises (42). In controlled trials where resistance training was clearly progressed, and intensity targets were specified, between-group findings were most evident for key strength outcomes, with one study reporting between-group differences favoring the concurrent training group for outcomes such as leg press 1RM and handgrip strength (38). Arm-specific changes were also reported in one study, showing differential effects on upper-limb measures in the concurrent training arm compared with the control (34). Collectively, these findings suggest that resistance exercise within concurrent training may help counteract treatment-related deconditioning and muscle loss, although the strength of this interpretation is limited by the inconsistency of comparative evidence across studies. Body composition outcomes were less consistently reported, although they were assessed within controlled designs. In trials reporting these endpoints, between-group differences were observed for select indicators in one study (38). Findings from another study further suggest that training dose, progression, and intervention duration may be important determinants of body composition responses (34). From a FITT-VP perspective, concurrent training protocols that combine resistance loads maintained at ≥60% 1RM (and progressed within 60–80% 1RM), with sets performed close to failure (≈1–3 repetitions in reserve), regular load adjustment, and adequate intervention duration (e.g., 8–20 weeks) may be more likely to produce favorable strength-related adaptations than lower-dose or minimally progressed approaches (38,40,44,64). Strength gains are consistent with protocols that included structured resistance progression, which may be especially important during phases associated with deconditioning risk, while body composition responses likely depend on intervention duration and training dose across phases (65,66). Effect of concurrent training on psychological outcomes and perceived well-being Patient-reported outcomes showed favorable changes in several studies, particularly in domains reflecting emotional well-being, anxiety, and sleep, although effects were not uniform across instruments or designs (30,39,67-69). Statistically significant within-group changes were reported for FACT-L Emotional Well-Being in three studies (31,32,39), HADS anxiety decreased in three studies (32,39,42), and sleep quality improved as reflected by a decrease in PSQI in one study (41). Additional patient-reported domains showed favorable changes in some studies, including selected quality-of-life and symptom measures (37,40,42), but these findings were more variable across instruments and time points. This variability likely reflects differences in baseline symptom burden, treatment phase, supervision, and social support inherent to supervised programs, as well as the responsiveness and scoring direction of different questionnaires. A plausible interpretation is that concurrent training may influence psychological outcomes both indirectly through favorable changes in physical function and symptom tolerance, and directly, through behavioral and psychosocial mechanisms, including increased self-efficacy and structured support (70-72). Patient-reported outcomes may be particularly sensitive to supervision and symptom burden, which can vary across treatment phases and may partly explain heterogeneity across instruments and time points (37,70,73-76). Strengths and limitations This review has several strengths. It provides a focused synthesis of concurrent training in people with lung cancer, examines a broad range of clinically relevant outcomes, and characterizes the interventions using the FITT-VP framework, thereby offering a more structured interpretation of exercise prescription across studies. By considering pulmonary function as the primary outcome while also integrating physical fitness, body composition, and patient-reported domains, the review contributes to a more comprehensive understanding of how concurrent training may influence adaptation across the lung cancer continuum. However, the findings should be interpreted with important limitations in mind. The current evidence base is characterized by small sample sizes, substantial methodological heterogeneity, and inconsistent reporting of exercise prescription, monitoring, progression, adherence, and adverse events, which restricts dose-response inference and limits cross-study comparability. In addition, the included studies spanned different phases of the cancer care continuum, from active treatment to postoperative recovery and longer-term survivorship, which may have influenced responsiveness to training and increased clinical heterogeneity. This review adopted a structured narrative synthesis because clinical and methodological heterogeneity, inconsistent outcome reporting, variable comparator conditions, and insufficient data for comparable between-group effect size calculation precluded meaningful pooling. Percentage-difference metrics were used only as descriptive indicators of within-group change and should not be interpreted as evidence of intervention efficacy or as a substitute for standardized between-group effect estimates. These metrics do not isolate the effect of concurrent training and may be influenced by spontaneous recovery, natural postoperative improvement, regression to the mean, time effects, and baseline severity differences, particularly in perioperative studies. Although a supplementary CENTRAL search was conducted to improve retrieval completeness, independent grey literature and standalone trial registry searches were not performed; therefore, the possibility of missed unpublished or difficult-to-index studies cannot be fully excluded. Feasibility and safety outcomes were not consistently reported across the included studies. Although information on adherence, retention, completion, and adverse events was extracted when available, these indicators were heterogeneous and were not reported in all studies. Therefore, no firm conclusions can be drawn regarding intervention fidelity, feasibility, or safety. Finally, risk of bias concerns, particularly confounding in non-randomized studies and limitations in allocation concealment and blinding in randomized trials, reduce the certainty of the available evidence. Clinical implications and future directions Despite these constraints, the available evidence suggests that concurrent training may be a promising supportive exercise approach for exercise capacity, functional performance, and muscular strength in people with lung cancer, particularly when programs are individualized, supervised when feasible, and progressed according to clinical status and symptom tolerance. However, the strength of these conclusions is limited by heterogeneous study designs, small sample sizes, inconsistent between-group findings, and risk of bias. In addition, because adherence, retention, completion, intervention fidelity, and adverse events were not consistently reported across studies, conclusions regarding feasibility and safety should be interpreted cautiously. From an implementation perspective, these findings may support the development of referral pathways to supervised or hybrid exercise-oncology services and the integration of FITT-VP guided prescription within multidisciplinary cancer care. Phase-tailored FITT-VP exercise prescription considerations, derived from the protocols included in this review, are presented in Table 2. Rather than proposing a single “optimal” protocol or formal clinical recommendations, Table 2 summarizes the most commonly used FITT-VP dose ranges across the included interventions. Given the small number of studies, methodological heterogeneity, inconsistent reporting, and risk of bias, these statements should be interpreted as low-certainty, evidence-informed guidance to support clinical reasoning and future research, rather than as strong or definitive recommendations. Future research should prioritize adequately powered randomized controlled trials with standardized reporting of FITT-VP parameters, adherence, supervision level, progression strategies, and adverse events. Longer follow-up is required to evaluate the sustainability of adaptations and to determine whether benefits differ by treatment phase, disease stage, and baseline functional status. A harmonized core outcome set, including pulmonary outcomes beyond spirometry alongside exercise capacity, strength, body composition, and patient-reported domains, would further improve comparability and strengthen the evidence supporting phase-specific prescription. Importantly, the considerations presented in Table 2 are intended to support evidence-informed practice rather than replace clinical judgment. Exercise prescription should be individualized according to treatment-related symptoms, comorbidities, functional capacity, safety considerations, and patient preferences, and adjusted dynamically over time. When embedded within multidisciplinary care pathways, concurrent training may represent a scalable approach to support physical function, quality of life, and rehabilitation across the lung cancer trajectory. Conclusions Concurrent training may be associated with favorable changes in exercise capacity, functional performance, and muscular strength in people with lung cancer, whereas pulmonary function outcomes appear less consistently responsive. However, these findings should be interpreted cautiously because several observed changes were based on within-group pre-post comparisons, while between-group superiority was inconsistent across outcomes and study designs. Current evidence is further limited by small sample sizes, heterogeneous study designs and exercise prescriptions, short follow-up, inconsistent reporting of intervention dose and progression, and risk of bias. Moreover, feasibility and safety could not be firmly established because adherence, retention, completion, intervention fidelity, and adverse events were not consistently reported across studies. Therefore, concurrent training should be viewed as a promising, but still low-certainty, supportive exercise approach rather than a definitively established intervention. Future research should prioritize adequately powered randomized trials with standardized FITT-VP reporting, systematic adherence and safety monitoring, longer follow-up, and harmonized core outcomes to strengthen phase-specific exercise prescription considerations. Supplementary The article’s supplementary files as Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-0424/prf